Commissioner Olivér Várhelyi Proposes EU Biotech Act to Streamline Innovation, Clinical Trials, and Manufacturing

Vision for EU Biotech Innovation Commissioner Olivér Várhelyi outlined his vision during a fireside chat at the BIO International Convention 2025, emphasizing biotechnology as a cornerstone for Europe’s future healthcare innovation. He stressed that Europe aims to leverage its high-quality healthcare data, innovation capacity, and manufacturing to become a global leader in new therapies over the next five years. To achieve this, he called for simplification and acceleration of regulatory processes to facilitate faster market access for novel therapies.

Key Proposals and Strategy Várhelyi announced plans for a new legislative framework, the Biotech Act, expected in 2026. The Act intends to integrate evolving technologies such as gene therapy, artificial intelligence, and data-driven biotech under one future-proof regulatory umbrella. Particular attention will be paid to modernizing clinical trial procedures, promoting EU manufacturing, and cutting red tape—efforts supported by the ongoing pharma review and Critical Medicines Act aimed at addressing supply chain vulnerabilities by incentivizing reshoring and expanding production capacity in Europe.

Balancing Innovation and Access The Commissioner underscored resolving the perceived tension between innovation and access, highlighting market failures as the root issue. The Critical Medicines Act seeks to create market conditions encouraging supply for rare diseases and chronic conditions. He also discussed increasing EU regulatory cooperation with the FDA to shorten delays in clinical trials and mutual recognition of dossiers.

Stakeholder Impact For the pharmaceutical industry, these reforms promise reduced regulatory complexity and faster clinical trials, potentially lowering costs. EU manufacturers may benefit from incentives and authorization streamlining to reshore production, enhancing supply security. Patients could gain faster access to innovative therapies, particularly for rare diseases and oncology. Conversely, national authorities will face challenges implementing harmonized regulations and accelerated review timelines. Overall, Várhelyi’s proposals point towards strengthened EU biotech capabilities with a focus on global competitiveness and patient-centered delivery.